SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52153 679 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51978Who knew that the invasion of Ukraine would affect MS drug trials? I was surpriA.J. Mullen-8/4/2022
51977Congrats to you this morning!A.J. Mullen-8/4/2022
51976CCXI being acquired by AMGN for $52. Another one I bought out of about 30.JamesK-8/4/2022
51975Thanks, and I agree completely about hedging. Risk management is the optimal roA.J. Mullen-8/3/2022
51974Hey congrats. I think hedging a bit was still a good strategy. Some of my sharesJamesK-8/3/2022
51973AI: From Drug Discovery To Robotics [graphic] Steve Nouri Forbes Councils MembFrank Sully-7/28/2022
51972That's my point. The amyloid beta research is now suspect and many, if not Art Bechhoefer-7/26/2022
51971Good luck to you and patients, current and future with tau tangles. There have A.J. Mullen-7/25/2022
51970Most companies involved in Alzheimers research have focussed on Amyloid beta plaArt Bechhoefer-7/25/2022
51969Thanks again for bringing the prices of options in ALNY to my attention. I sold A.J. Mullen-7/24/2022
51968Questions regarding the integrity of data for a key 2006 Nature paper underpinniA.J. Mullen-7/24/2022
51967PLRX data in IPF news releaseJamesK17/11/2022
51966An article in today's online issue of BARRON'S notes that there is upwarArt Bechhoefer-7/8/2022
51965Volatility for sure. Stock needs to move 20% just to break even on the options. JamesK-7/2/2022
51964I don't follow options having been burnt too often, but there must be informA.J. Mullen-7/2/2022
51963Take a look at the AUG option premiums in ALNY right now. I still think the 2.5 JamesK-7/1/2022
51962Surely Onpattro has potential adverse side effects, but it does not have a blackA.J. Mullen-6/16/2022
51961Tegsedi, the drug developed by Ionis Pharmaceuticals, is injected by the patientArt Bechhoefer-6/16/2022
51960I hold some ALNY. Alnylam will be putting vitrisiran up against its own OnpattrA.J. Mullen-6/16/2022
51959Competition for Ions and others. ArtArt Bechhoefer-6/14/2022
51958Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran) finance.yahoo.comA.J. Mullen-6/14/2022
51957Researchers use CRISPR technology to create map tying every human gene to its fuSavant16/10/2022
51956FTC (at long last) launches PBM inquiry: ftc.gov This is bullish for drug/biDewDiligence_on_SI16/7/2022
51955Shame on me for not knowing anything of BBIO. The results they posted are surprA.J. Mullen-6/6/2022
51954A Cancer Trial's Unexpected Result: Remission in Every Patient It was a smaAloner16/6/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News